← Back to guidelines
Cardiology1 paper

Mucin-producing adenocarcinoma

Last edited: 5 h ago

Overview

Mucin-producing adenocarcinomas are a subset of adenocarcinomas characterized by the excessive production of mucin, which can contribute to clinical syndromes including nonbacterial thrombotic endocarditis (NBTE) and disseminated thrombosis 1.

Diagnosis

  • Histochemical staining to identify mucinous substance in tumor tissue and thrombi 1.
  • Circulating mucinous substance detected in blood may precede clinical manifestations of NBTE 1.
  • Imaging studies (e.g., echocardiography) to identify valvular vegetations and thrombotic events 1.
  • Management

  • No specific drug doses mentioned; focus on managing complications such as thrombosis.
  • Anticoagulation therapy to prevent and manage thrombotic events 1.
  • Surgical resection of the primary tumor when feasible 1.
  • Special Populations

  • No specific guidance provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.
  • Key Recommendations

  • Consider histochemical staining to evaluate the presence of mucinous substance in both tumor tissue and thrombi for diagnosing mucin-producing adenocarcinomas associated with NBTE (Evidence: Moderate) 1.
  • Initiate anticoagulation therapy in patients with mucin-producing adenocarcinomas at risk for or presenting with thrombotic complications (Evidence: Moderate) 1.
  • Evaluate for circulating mucinous substance as a potential early indicator of impending NBTE in patients with mucin-producing adenocarcinomas (Evidence: Weak) 1.
  • References

    1 Min KW, Gyorkey F, Sato C. Mucin-producing adenocarcinomas and nonbacterial thrombotic endocarditis: pathogenetic role of tumor mucin. Cancer 1980. link45:9<2374::aid-cncr2820450923>3.0.co;2-j)

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Pricing·Privacy & Terms·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG